WSO - February 2023 - 125

Protocols
A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible,
237
late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design
Gregory W Albers, Bruce CV Campbell, Maarten G Lansberg, Joseph Broderick, Ken Butcher, Michael T Froehler, Lee H Schwamm, Amre M Nouh,
David S Liebeskind, Florence Toy, Ming Yang, Lori Massaro, Megan Schoeffler and Barbara Purdon
Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage (FINISHER) trial:
Study protocol for a randomized controlled trial
Erdem Güresir, Tim Lampmann, Sylvia Bele, Marcus Czabanka, Patrick Czorlich, Jens Gempt, Roland Goldbrunner, Helene Hurth, Elvis Hermann,
Ramazan Jabbarli, Marius Krauthausen, Ralph König, Dirk Lindner, Vesna Malinova, Jürgen Meixensberger, Dorothee Mielke, Robert Németh,
Marvin Darkwah Oppong, Andrej Pala, Vincent Prinz, Ali Rashidi, Constantin Roder, Ibrahim Erol Sandalcioglu, Thomas Sauvigny, Karl-Michael Schebesch,
Marco Timmer, Peter Vajkoczy, Lars Wessels, Florian Wild, Christoph Wilhelm, Maria Wostrack, Hartmut Vatter and Christoph Coch
Letters to the editor
Vertebrobasilar ischemia: Some less recognized aspects
242
248
Visit journals.sagepub.com/home/wso
Free access to tables of contents and abstracts. Site-wide access to the full text for members of
subscribing institutions.

http://journals.sagepub.com/home/wso

WSO - February 2023

Table of Contents for the Digital Edition of WSO - February 2023

February 2023
WSO - February 2023 - Cover1
WSO - February 2023 - 122
WSO - February 2023 - 123
WSO - February 2023 - February 2023
WSO - February 2023 - 125
WSO - February 2023 - 126
WSO - February 2023 - 127
WSO - February 2023 - 128
WSO - February 2023 - 129
WSO - February 2023 - 130
WSO - February 2023 - 131
WSO - February 2023 - 132
WSO - February 2023 - 133
WSO - February 2023 - 134
WSO - February 2023 - 135
WSO - February 2023 - 136
WSO - February 2023 - 137
WSO - February 2023 - 138
WSO - February 2023 - 139
WSO - February 2023 - 140
WSO - February 2023 - 141
WSO - February 2023 - 142
WSO - February 2023 - 143
WSO - February 2023 - 144
WSO - February 2023 - 145
WSO - February 2023 - 146
WSO - February 2023 - 147
WSO - February 2023 - 148
WSO - February 2023 - 149
WSO - February 2023 - 150
WSO - February 2023 - 151
WSO - February 2023 - 152
WSO - February 2023 - 153
WSO - February 2023 - 154
WSO - February 2023 - 155
WSO - February 2023 - 156
WSO - February 2023 - 157
WSO - February 2023 - 158
WSO - February 2023 - 159
WSO - February 2023 - 160
WSO - February 2023 - 161
WSO - February 2023 - 162
WSO - February 2023 - 163
WSO - February 2023 - 164
WSO - February 2023 - 165
WSO - February 2023 - 166
WSO - February 2023 - 167
WSO - February 2023 - 168
WSO - February 2023 - 169
WSO - February 2023 - 170
WSO - February 2023 - 171
WSO - February 2023 - 172
WSO - February 2023 - 173
WSO - February 2023 - 174
WSO - February 2023 - 175
WSO - February 2023 - 176
WSO - February 2023 - 177
WSO - February 2023 - 178
WSO - February 2023 - 179
WSO - February 2023 - 180
WSO - February 2023 - 181
WSO - February 2023 - 182
WSO - February 2023 - 183
WSO - February 2023 - 184
WSO - February 2023 - 185
WSO - February 2023 - 186
WSO - February 2023 - 187
WSO - February 2023 - 188
WSO - February 2023 - 189
WSO - February 2023 - 190
WSO - February 2023 - 191
WSO - February 2023 - 192
WSO - February 2023 - 193
WSO - February 2023 - 194
WSO - February 2023 - 195
WSO - February 2023 - 196
WSO - February 2023 - 197
WSO - February 2023 - 198
WSO - February 2023 - 199
WSO - February 2023 - 200
WSO - February 2023 - 201
WSO - February 2023 - 202
WSO - February 2023 - 203
WSO - February 2023 - 204
WSO - February 2023 - 205
WSO - February 2023 - 206
WSO - February 2023 - 207
WSO - February 2023 - 208
WSO - February 2023 - 209
WSO - February 2023 - 210
WSO - February 2023 - 211
WSO - February 2023 - 212
WSO - February 2023 - 213
WSO - February 2023 - 214
WSO - February 2023 - 215
WSO - February 2023 - 216
WSO - February 2023 - 217
WSO - February 2023 - 218
WSO - February 2023 - 219
WSO - February 2023 - 220
WSO - February 2023 - 221
WSO - February 2023 - 222
WSO - February 2023 - 223
WSO - February 2023 - 224
WSO - February 2023 - 225
WSO - February 2023 - 226
WSO - February 2023 - 227
WSO - February 2023 - 228
WSO - February 2023 - 229
WSO - February 2023 - 230
WSO - February 2023 - 231
WSO - February 2023 - 232
WSO - February 2023 - 233
WSO - February 2023 - 234
WSO - February 2023 - 235
WSO - February 2023 - 236
WSO - February 2023 - 237
WSO - February 2023 - 238
WSO - February 2023 - 239
WSO - February 2023 - 240
WSO - February 2023 - 241
WSO - February 2023 - 242
WSO - February 2023 - 243
WSO - February 2023 - 244
WSO - February 2023 - 245
WSO - February 2023 - 246
WSO - February 2023 - 247
WSO - February 2023 - 248
WSO - February 2023 - 249
WSO - February 2023 - 250
WSO - February 2023 - 251
WSO - February 2023 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com